Publications Prof. Dr. S. Dove (since 1991)

2006-2010 2001-2005 1996-2000 1991-1995

R. Seifert, S. Dove, Towards selective inhibitors of adenylyl cyclase toxin from Bordetella pertussis. Trends Microbiol 20, 343-351 (2012)

R. Seifert, S. Dove, Molecular analysis of agonist stereoisomers at β2-adrenoceptors. In: K. Jozwiak, W.J. Lough, I.W. Wainer (Eds.) Drug stereochemistry : analytical methods and pharmacology Vol. 211, Informa Healthcare, New York, 2012, pp. 274-293

M. Göttle, S. Dove, R. Seifert, Bacillus anthracis edema factor substrate specificity: evidence for new modes of action. Toxins (Basel) 4, 505-535 (2012)

T. Birnkammer, A. Spickenreither, I. Brunskole, M. Lopuch, N. Kagermeier, G. Bernhardt, S. Dove, R. Seifert, S. Elz, A. Buschauer, The bivalent ligand approach leads to highly potent and selective acylguanidine-type histamine H(2) receptor agonists. J. Med. Chem. 55, 1147-1160 (2012)

H. Appl, T. Holzammer, S. Dove, E. Haen, A. Strasser, R. Seifert, Interactions of recombinant human histamine H(1), H(2), H(3), and H(4) receptors with 34 antidepressants and antipsychotics, Naunyn-Schmiedebergs Arch. Pharmacol. 385, 145-170 (2012)

H. Taha, S. Dove, J. Geduhn, B. Konig, Y. Shen, W.J. Tang, R. Seifert, Inhibition of the adenylyl cyclase toxin, edema factor, from Bacillus anthracis by a series of 18 mono- and bis-(M)ANT-substituted nucleoside 5'-triphosphates, Naunyn- Schmiedebergs Arch. Pharmacol. 385, 57-68 (2012)

M.E. Silva, R. Heim, A. Strasser, S. Elz, S. Dove, Theoretical studies on the interaction of partial agonists with the 5-HT(2A) receptor. J. Comput. Aided Mol. Des. 25, 51-66 (2011)

R. Seifert, E.H. Schneider, S. Dove, I. Brunskole, D. Neumann, A. Strasser, A. Buschauer, Paradoxical stimulatory effects of the "standard" histamine H4-receptor antagonist JNJ7777120: The H4-receptor joins the club of 7TM receptors exhibiting functional selectivity. Mol. Pharmacol. 79, 631-638 (2011)

D. Schnell, I. Brunskole, K. Ladova, E.H. Schneider, P. Igel, S. Dove, A. Buschauer, R. Seifert, Expression and functional properties of canine, rat, and murine histamine H(4) receptors in Sf9 insect cells. Naunyn-Schmiedebergs Arch. Pharmacol. 383, 457-470 (2011)

J. Geduhn, S. Dove, Y. Shen, W.J. Tang, B. König, R. Seifert, Bis-Halogen-Anthraniloyl-Substituted Nucleoside 5'-triphosphates as Potent and Selective Inhibitors of Bordetella pertussis CyaA. J. Pharmacol. Exp. Ther. 336, 104-115 (2011)

S. Braun, A. Botzki, S. Salmen, C. Textor, G. Bernhardt, S. Dove, A. Buschauer, Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase, Eur. J. Med. Chem. 46, 4419-4429 (2011) 

E.H. Schneider, D. Schnell, A. Strasser, S. Dove, R. Seifert, Impact of the DRY Motif and the Missing "Ionic Lock" on Constitutive Activity and G-Protein Coupling of the Human Histamine H4 Receptor. J. Pharmacol. Exp. Ther. 333, 382-392 (2010)

M. Göttle, S. Dove, F. Kees, J. Schlossmann, J. Geduhn, B. König, Y.Q. Shen, W.J. Tang, V. Kaever, R. Seifert, Cytidylyl and Uridylyl Cyclase Activity of Bacillus anthracis Edema Factor and Bordetella pertussis CyaA. Biochemistry 49, 5494-5503 (2010)

P. Ghorai, A. Kraus, T. Birnkammer, R. Geyer, G. Bernhardt, S. Dove, R. Seifert, S. Elz, A. Buschauer, Chiral N-G-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity. Bioorg. Med. Chem. Lett. 20, 3173-3176 (2010)

P. Igel, S. Dove, A. Buschauer, Histamine H4 receptor agonists. Bioorg. Med. Chem. Lett. 20, 7191-7199 (2010)

P. Igel, R. Geyer, A. Strasser, S. Dove, R. Seifert, A. Buschauer, Synthesis and Structure-Activity Relationships of Cyanoguanidine-Type and Structurally Related Histamine H4 Receptor Agonists. J. Med. Chem. 52, 6297-6313 (2009)

S. Mahboobi, S. Dove, A. Sellmer, M. Winkler, E. Eichhorn, H. Pongratz, T. Ciossek, T. Baer, T. Maier, T. Beckers, Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-type and Mutant BCR-ABL, PDGF-Rß and Histone Deacetylases. J. Med. Chem. 52, 2265-2279 (2009)

H.M. Taha, J. Schmidt, M. Göttle, S. Suryanarayana, Y. Shen, W.-J. Tang, A. Gille, J. Geduhn, B. König, S. Dove, R. Seifert, Molecular Analysis of the Interaction of Anthrax Adenylyl Cyclase Toxin, Edema Factor, with 2'(3')-O-(N-(methyl)anthraniloyl)-Substituted Purine and Pyrimidine Nucleotides. Mol. Pharmacol. 75, 693-703 (2009)

R. Seifert, S. Dove, Functional Selectivity of GPCR Ligand Stereoisomers: New Pharmacological Opportunities. Mol. Pharmacol. 75, 13-18 (2009)

A. Kraus, P. Ghorai, T. Birnkammer, D. Schnell, S. Elz, R. Seifert, S. Dove, G. Bernhardt, A. Buschauer, N(G)-Acylated aminothiazolylpropylguanidines as potent and selective histamine H2 receptor agonists. ChemMedChem 4, 232-240 (2009)

P. Ghorai, A. Kraus, M. Keller, C. Götte, P. Igel, E. Schneider, D. Schnell, G. Bernhardt, S. Dove, M. Zabel, S. Elz, R. Seifert, A. Buschauer, Acylguanidines as bioisosteres of guanidines: N(G)-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists. J. Med. Chem. 51, 7193-7204 (2008)

S. Dove, R. Seifert, S. Elz, A. Buschauer, Frontiers in Medicinal Chemistry in Regensburg. ChemMedChem 3, 1181-1184 (2008)

H. Preuss, P. Ghorai, A. Kraus, S. Dove, A. Buschauer, R. Seifert, Point Mutations in the Second Extracellular Loop of the Histamine H2 Receptor do not affect the Species-Selective Activity of Guanidine-Type Agonists. Naunyn Schmiedebergs Arch. Pharmacol. 376, 253-264 (2007)

H. Preuss, P. Ghorai, A. Kraus, S. Dove, A. Buschauer, R. Seifert, Mutations of Cys-17 and Ala-271 in the human histamine H2 receptor determine the species-selectivity of guanidine-type agonists and increase constitutive activity. J. Pharmacol. Exp. Ther. 321, 975-982 (2007)

H. Preuss, P. Ghorai, A. Kraus, S. Dove, A. Buschauer, R. Seifert, Constitutive activity and ligand selectivity of human, guinea pig, rat, and canine histamine H2 receptors. J. Pharmacol. Exp. Ther. 321, 983-995 (2007)

S. Mahboobi, A. Uecker, C. Cenac, A. Sellmer, E. Eichhorn, S. Elz, F.-D. Böhmer, S. Dove, Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg. Med. Chem. 15, 2187-2197 (2007)

M. Göttle, S. Dove, P. Steindel, Y. Shen, W.-J. Tang, J. Geduhn, B. König, R. Seifert, Molecular analysis of the interaction of Bordetella pertussis adenylyl cyclase with fluorescent nucleotides. Mol. Pharmacol. 72, 526-535 (2007)

M. Spickenreither, S. Braun, G. Bernhardt, S. Dove, A. Buschauer, Novel 6-O-acylated vitamin C derivatives as hyaluronidase inhibitors with selectivity for bacterial lyases. Bioorg. Med. Chem. Lett. 16, 5313-5316 (2006)

D.J. Rigden, A. Botzki, M. Nukui, R.B. Mewbourne, E. Lamani, S. Braun, E. v.Angerer, G. Bernhardt, S. Dove, A. Buschauer, M.J. Jedrzejas, Design of New Benzoxazole-2-Thione Derived Inhibitors of Streptococcus pneumoniae Hyaluronan Lyase: Structure of a Complex with a 2-Phenylindole. Glycobiology 16, 757-765 (2006)

S. Mahboobi, A. Uecker, A. Sellmer, C. Cénac, H. Höcher, H. Pongratz, H. Hufsky, A. Trümpler, M. Sicker, F. Heidel, T. Fischer, C. Stocking, S. Elz, F.-D. Böhmer, S. Dove, Novel bis-(1H-indol-2-yl)-methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 49, 3101-3115 (2006)

2001-2005

A. Botzki, S. Salmen, G. Bernhardt, A. Buschauer, S. Dove, Structure-based design of bacterial hyaluronan lyase inhibitors. QSAR Comb. Sci. 24, 458-469 (2005)

S. Dove, S. Elz, R. Seifert, A. Buschauer, Structure-Activity Relationships of H2 Receptor Ligands. Mini. Rev. Med. Chem. 4, 941-954 (2004)

S. Dove, Picolinic Acids as Inhibitors of Dopamine β-Monooxygenase: QSAR and Putative Binding Site. Arch. Pharm. (Weinheim) 337, 645-653 (2004)

A. Brennauer, S. Dove, A. Buschauer, Structure-Activity Relationships of Non-Peptide NPY Receptor Antagonists. In: M.C. Michel (Ed.) Neuropeptide Y and Related Peptides, Handbook of Experimental Pharmacology Vol. 162, Springer, Heidelberg, 2004, pp. 506 - 544

A. Botzki, D.J. Rigden, S. Braun, M. Nukui, S. Salmen, J. Hoechstetter, G. Bernhardt, S. Dove, M.J. Jedrzejas, A. Buschauer, L-ascorbic acid-6-hexadecanoate, a potent hyaluronidase inhibitor: X-ray structure and molecular modeling of enzyme-inhibitor complexes. J. Biol. Chem. 279, 45990-45997 (2004)

R. Seifert, K. Wenzel-Seifert, T. Bürckstümmer, H.H. Pertz, W. Schunack, S. Dove, A. Buschauer, S. Elz, Multiple differences in agonist- and antagonist pharmacology between human and guinea pig histamine H1-receptor. J. Pharmacol. Exp. Ther. 305, 1104-1115 (2003)

J. Radons, S. Dove, D. Neumann, R. Altmann, A. Botzki, M.U. Martin, W. Falk, The IL-1 receptor accessory protein TIR domain: analysis of putative interaction sites by in-vitro mutagenesis and molecular modeling. J. Biol. Chem. 278, 49145-49153 (2003)

F.D. Böhmer, L. Karagyozov, A. Uecker, H. Serve, A. Botzki, S. Mahboobi, S. Dove, A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP-site inhibitor STI-571. J. Biol. Chem. 278, 5148-5155 (2003)

S. Mahboobi, S. Teller, H. Pongratz, H. Hufsky, A. Sellmer, A. Botzki, A. Uecker, T. Beckers, S. Baasner, C. Schächtele, F. Überall, M.U. Kassack, S. Dove, F.-D. Böhmer, Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase. J. Med. Chem. 45, 1002-1018 (2002)

M.T. Kelley, T. Bürckstümmer, K. Wenzel-Seifert, S. Dove, A. Buschauer, R. Seifert, Distinct interaction of human and guinea pig histamine H2-receptor with guanidine-type agonists. Mol. Pharmacol. 60, 1210-1225 (2001)

S. Dove, Alignment of molecules by weighted field fit considering active shape. In: H.-D. Höltje, W. Sippl (Eds.) Rational Approaches to Drug Design - 13th European Symposium on QSAR, J. R. Prous Science, S. A., Barcelona, Philadelphia, 2001, pp. 316-322

S. Dove, Arzneistoffe aus dem Computer – Modellierung molekularer Schlüssel für biologische Schlösser. Blick in die Wissenschaft (Forschungsmagazin Univ. Regensburg) 13, 22-26 (2001)

1996-2000

S. Dove, M.C. Michel, S. Knieps, A. Buschauer, Pharmacology and quantitative structure-activity relationships of imidazolyl-propylguanidines with mepyramine-like substructures as non-peptide neuropeptide Y Y1 antagonists. Can. J. Physiol. Pharmacol. 78, 108-115 (2000)

A. Buschauer, G. Bernhardt, S. Dove, Neuropeptid Y - NPY-Rezeptoren als Zielstrukturen für neue Arzneistoffe. Pharmazeutische Zeitung 2000, 11-18 (2000)

I. Aiglstorfer, I. Hendrich, C. Moser, G. Bernhardt, S. Dove, A. Buschauer, Structure-Activity Relationships of Neuropeptide Y Y1 Receptor Antagonists Related to BIBP 3226. Bioorg. Med. Chem. Lett. 10, 1597-1600 (2000)

S. Mahboobi, S. Dove, S. Kuhr, A. Popp, Homo-arcyriaflavin: The synthesis of ring-expanded arcyriaflavin analogs. J. Org. Chem. 64, 8130-8137 (1999)

S. Mahboobi, S. Dove, S. Kuhr, H. Pongratz, Synthesis of arcyriarubine regioisomers by Pd(0)-catalysis or via lithiated indole derivatives - conformational analysis by semiempirical and X-ray methods. Pharmazie 54, 820-827 (1999)

S. Dove, A. Buschauer, Improved alignment by weighted field fit in CoMFA of histamine H2 receptor agonistic imidazolylpropyl-guanidines. Quant. Struct.-Act. Relat. 18, 329-341 (1999)

K.K. Mayer, S. Dove, H. Pongratz, M. Ertan, W. Wiegrebe, Electron impact induced fragmentation of 4-aryl-4,6,7,8-tetrahydro-1H,3H-quinazolinone-2,5-diones. Heterocycles 48, 1169-1183 (1998)

S. Dove, A. Buschauer, Imidazolylpropylguanidines as Histamine H2 Receptor Agonists: 3D-QSAR of a Large Series. Pharm. Acta Helv. 73, 145-155 (1998)

S. Dove, Computermethoden im Arzneimitteldesign. In: L. Lehner, G. Braungart, L. Hitzenberger (Eds.) Multimedia in Lehre und Forschung, Gabler Verlag, Deutscher Universitäts-Verlag, Wiesbaden, 1998, pp. 75 - 88

I. Aiglstorfer, A. Uffrecht, K. Gessele, C. Moser, A. Schuster, S. Merz, B. Malawska, G. Bernhardt, S. Dove, A. Buschauer, Nonpeptide NPY Y1 antagonists: Structure-activity relationships of arginine derivatives and hybrid compounds with arpromidine-like partial structures. Regul. Pept. 75-76 , 9-21 (1998)

M. Müller, S. Knieps, K. Gessele, S. Dove, G. Bernhardt, A. Buschauer, Synthesis and neuropeptide Y Y1 receptor antagonistic activity of N,N-disubstituted  ω-guanidino and ω-aminoalkanoic acid amides. Arch. Pharm. 330, 333-342 (1997)

G. Märkl, J. Stiegler, P. Kreitmeier, T. Burgemeister, F. Kastner, S. Dove, Configurational and conformational isomeric antiaromatic [28]tetraoxaporphyrinoids(4.2.4.2) and aromatic [26]tetraoxaporphyrin(4.2.4.2) dications. A new type of molecular dynamics in macrocyclic systems. Helv. Chim. Acta 80, 14-42 (1997)

S. Mahboobi, S. Dove, P.J. Bednarski, S. Kuhr, T. Burgemeister, D. Schollmeyer, X-Ray Crystal Structure of Woodinine and Conformational Analysis by Means of Semiempirical and 1H-NMR Methods. J. Nat. Prod. 60, 587-591 (1997)

S. Dove, A. Buschauer, Stepwise Leave-One-Isomer-Out Free-Wilson Approaches as Preprocessing Tools in QSAR Analysis of Racemates. Quant. Struct.-Act. Relat. 16, 11-19 (1997)

S. Knieps, S. Dove, M.C. Michel, K. Rottmeier, W. Werner, G. Bernhardt, A. Buschauer, ω-Phenyl-ω-(2-pyridyl)alkyl-substituted bisguanidines are moderate neuropeptide Y antagonists. Pharm. Pharmacol. Lett. 6, 27-30 (1996)

1991-1995

M.J. Mokrosz, L. Strekowski, W.X. Kosak, B. Duszynska, A.J. Bojarski, A. Klodzinska, A. Czarny, M.T. Cegla, A. Deren-Wesolek, E. Chojnacka-Wojcik, S. Dove, J.L. Mokrosz, 4,6-Di(heteroaryl)-2-(N-methylpiperazino)pyrimidines as New, Potent 5-HT2A Receptor Ligands: A Verification of the Topographic Model. Arch. Pharm. 328, 659-666 (1995)

S. Knieps, M.C. Michel, S. Dove, A. Buschauer, Non-Peptide Neuropeptide Y Antagonists Derived from the Histamine H2 Agonist Arpromidine: Role of the Guanidine Group. Bioorg. Med. Chem. Lett. 5, 2065-2070 (1995)

S. Dove, R. Kühne, W. Schunack, H1 agonistic 2-heteroaryl and 2-phenylhistamines: CoMFA and possible receptor binding sites. In: F. Sanz, J. Giraldo, F. Manaut (Eds.) QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications, J. R. Prous Science Publ., Barcelona, 1995, pp. 427 - 432

R. Franke, S. Dove, A. Gruska, Physicochemical properties and drug action: alternative QSAR methods. In: P.N. Kouronnakis, E. Rekka (Eds.) Advanced Drug Design and Development, a Medicinal Chemistry Approach, Ellis Horwood Series in Pharmaceutical Technology, Ellis Horwood, London, 1994, pp. 43 - 97

S. Dove, H. Schönenberger, Estrogenic activity: An example of considering effectuation models in biological data interpretation and QSAR. In: C.G. Wermuth (Ed.) Trends in QSAR and Molecular Modelling, ESCOM, Leiden, 1993, pp. 554 - 555

S. Dove, H. Schönenberger, Computer modelling of estrogenic transcriptional activation can account for different types of dose-response curves of estrogens. J. Steroid Biochem. Molec. Biol. 46, 163-176 (1993)

S. Dove, R. Franke, Activity data decomposition - levels, methods and principles. In: C. Silipo (Ed.) QSAR: Rational approaches in the design of bioactive compounds, Pharmacochem. Libr. Vol. 16, Elsevier, Amsterdam, 1991, pp. 37 - 40

S. Dove, R. Franke, Model-based LFER parameters and QSAR of ligand-β-adrenoceptor interactions. II. Estimation and QSAR of agonistic potency and receptor affinity in a series of β-adrenergic phenethanolamines. Quant. Struct.-Act. Relat. 10, 23-31 (1991)

S. Dove, R. Franke, Model-based LFER parameters and QSAR of ligand-β-adrenoceptor interactions. I. Equilibrium models and parameters of β-adrenergic effectuation. Quant. Struct.-Act. Relat. 10, 16-22 (1991)

S. Dove, Theoretische Methoden in der Wirkstofforschung - Möglichkeiten und Grenzen. Medicamentum 32, 196-205 (1991)